Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies.

Kelliher MA, Roderick JE.

Front Immunol. 2018 Aug 20;9:1718. doi: 10.3389/fimmu.2018.01718. eCollection 2018. Review.

2.

BID-ding on necroptosis in MDS.

Croker BA, Kelliher MA.

Blood. 2019 Jan 10;133(2):103-104. doi: 10.1182/blood-2018-11-886242. No abstract available.

3.

Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death.

Orning P, Weng D, Starheim K, Ratner D, Best Z, Lee B, Brooks A, Xia S, Wu H, Kelliher MA, Berger SB, Gough PJ, Bertin J, Proulx MM, Goguen JD, Kayagaki N, Fitzgerald KA, Lien E.

Science. 2018 Nov 30;362(6418):1064-1069. doi: 10.1126/science.aau2818. Epub 2018 Oct 25.

4.

The pseudokinase MLKL activates PAD4-dependent NET formation in necroptotic neutrophils.

D'Cruz AA, Speir M, Bliss-Moreau M, Dietrich S, Wang S, Chen AA, Gavillet M, Al-Obeidi A, Lawlor KE, Vince JE, Kelliher MA, Hakem R, Pasparakis M, Williams DA, Ericsson M, Croker BA.

Sci Signal. 2018 Sep 4;11(546). pii: eaao1716. doi: 10.1126/scisignal.aao1716.

5.

Analyzing Necroptosis Using an RIPK1 Kinase Inactive Mouse Model of TNF Shock.

Zelic M, Kelliher MA.

Methods Mol Biol. 2018;1857:125-134. doi: 10.1007/978-1-4939-8754-2_12.

PMID:
30136236
6.

UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response.

Huiting LN, Samaha Y, Zhang GL, Roderick JE, Li B, Anderson NM, Wang YW, Wang L, Laroche F, Choi JW, Liu CT, Kelliher MA, Feng H.

Leukemia. 2018 Nov;32(11):2339-2351. doi: 10.1038/s41375-018-0141-x. Epub 2018 Apr 25.

7.

RIP kinase 1-dependent endothelial necroptosis underlies systemic inflammatory response syndrome.

Zelic M, Roderick JE, O'Donnell JA, Lehman J, Lim SE, Janardhan HP, Trivedi CM, Pasparakis M, Kelliher MA.

J Clin Invest. 2018 May 1;128(5):2064-2075. doi: 10.1172/JCI96147. Epub 2018 Apr 16.

8.

Correction: Dendritic Cell RIPK1 Maintains Immune Homeostasis by Preventing Inflammation and Autoimmunity.

O'Donnell JA, Lehman J, Roderick JE, Martinez-Marin D, Zelic M, Doran C, Hermance N, Lyle S, Pasparakis M, Fitzgerald KA, Marshak-Rothstein A, Kelliher MA.

J Immunol. 2018 Apr 15;200(8):3020-3021. doi: 10.4049/jimmunol.1800240. Epub 2018 Mar 12. No abstract available.

9.

ATACseqQC: a Bioconductor package for post-alignment quality assessment of ATAC-seq data.

Ou J, Liu H, Yu J, Kelliher MA, Castilla LH, Lawson ND, Zhu LJ.

BMC Genomics. 2018 Mar 1;19(1):169. doi: 10.1186/s12864-018-4559-3.

10.

Dendritic Cell RIPK1 Maintains Immune Homeostasis by Preventing Inflammation and Autoimmunity.

O'Donnell JA, Lehman J, Roderick JE, Martinez-Marin D, Zelic M, Doran C, Hermance N, Lyle S, Pasparakis M, Fitzgerald KA, Marshak-Rothstein A, Kelliher MA.

J Immunol. 2018 Jan 15;200(2):737-748. doi: 10.4049/jimmunol.1701229. Epub 2017 Dec 6. Erratum in: J Immunol. 2018 Mar 12;:.

11.

RIPK1 mediates a disease-associated microglial response in Alzheimer's disease.

Ofengeim D, Mazzitelli S, Ito Y, DeWitt JP, Mifflin L, Zou C, Das S, Adiconis X, Chen H, Zhu H, Kelliher MA, Levin JZ, Yuan J.

Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8788-E8797. doi: 10.1073/pnas.1714175114. Epub 2017 Sep 13.

12.

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia.

Choi A, Illendula A, Pulikkan JA, Roderick JE, Tesell J, Yu J, Hermance N, Zhu LJ, Castilla LH, Bushweller JH, Kelliher MA.

Blood. 2017 Oct 12;130(15):1722-1733. doi: 10.1182/blood-2017-03-775536. Epub 2017 Aug 8.

13.

BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.

Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE, Vittori S, Reyes JM, di Iulio J, Souza A, Ott CJ, Roberts JM, Zeid R, Scott TG, Paulk J, Lachance K, Olson CM, Dastjerdi S, Bauer S, Lin CY, Gray NS, Kelliher MA, Churchman LS, Bradner JE.

Mol Cell. 2017 Jul 6;67(1):5-18.e19. doi: 10.1016/j.molcel.2017.06.004. Epub 2017 Jun 29.

14.

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.

Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, Kelliher MA, Horton TM, Wood BL, Teachey DT, Hermiston ML.

Leukemia. 2017 Dec;31(12):2568-2576. doi: 10.1038/leu.2017.136. Epub 2017 May 9.

15.

Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.

Carr MI, Roderick JE, Zhang H, Woda BA, Kelliher MA, Jones SN.

Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):15024-15029. doi: 10.1073/pnas.1611798114. Epub 2016 Dec 12.

16.

CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.

Lian H, Li D, Zhou Y, Landesman-Bollag E, Zhang G, Anderson NM, Tang KC, Roderick JE, Kelliher MA, Seldin DC, Fu H, Feng H.

Haematologica. 2017 Jan;102(1):e17-e21. doi: 10.3324/haematol.2016.154013. Epub 2016 Oct 6. No abstract available.

17.

High-Throughput Screening of Tyrosine Kinase Inhibitor Resistant Genes in CML.

Ma L, Roderick J, Kelliher MA, Green MR.

Methods Mol Biol. 2016;1465:159-73. doi: 10.1007/978-1-4939-4011-0_14.

18.

Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis.

Carr MI, Roderick JE, Gannon HS, Kelliher MA, Jones SN.

Cell Rep. 2016 Sep 6;16(10):2618-2629. doi: 10.1016/j.celrep.2016.08.014. Epub 2016 Aug 25.

19.

RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS.

Ito Y, Ofengeim D, Najafov A, Das S, Saberi S, Li Y, Hitomi J, Zhu H, Chen H, Mayo L, Geng J, Amin P, DeWitt JP, Mookhtiar AK, Florez M, Ouchida AT, Fan JB, Pasparakis M, Kelliher MA, Ravits J, Yuan J.

Science. 2016 Aug 5;353(6299):603-8. doi: 10.1126/science.aaf6803.

20.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

21.

CYLD Proteolysis Protects Macrophages from TNF-Mediated Auto-necroptosis Induced by LPS and Licensed by Type I IFN.

Legarda D, Justus SJ, Ang RL, Rikhi N, Li W, Moran TM, Zhang J, Mizoguchi E, Zelic M, Kelliher MA, Blander JM, Ting AT.

Cell Rep. 2016 Jun 14;15(11):2449-61. doi: 10.1016/j.celrep.2016.05.032. Epub 2016 Jun 2.

22.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

23.

The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis.

Anderson NM, Li D, Peng HL, Laroche FJ, Mansour MR, Gjini E, Aioub M, Helman DJ, Roderick JE, Cheng T, Harrold I, Samaha Y, Meng L, Amsterdam A, Neuberg DS, Denton TT, Sanda T, Kelliher MA, Singh A, Look AT, Feng H.

Leukemia. 2016 Jun;30(6):1365-74. doi: 10.1038/leu.2016.26. Epub 2016 Feb 15.

24.

Deletion of the gene encoding G0/G 1 switch protein 2 (G0s2) alleviates high-fat-diet-induced weight gain and insulin resistance, and promotes browning of white adipose tissue in mice.

El-Assaad W, El-Kouhen K, Mohammad AH, Yang J, Morita M, Gamache I, Mamer O, Avizonis D, Hermance N, Kersten S, Tremblay ML, Kelliher MA, Teodoro JG.

Diabetologia. 2015 Jan;58(1):149-57. doi: 10.1007/s00125-014-3429-z. Epub 2014 Nov 9.

25.

Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis.

Roderick JE, Hermance N, Zelic M, Simmons MJ, Polykratis A, Pasparakis M, Kelliher MA.

Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14436-41. doi: 10.1073/pnas.1409389111. Epub 2014 Sep 22.

26.

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.

Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA Jr, Pelletier J, Rätsch G, Wendel HG.

Nature. 2014 Sep 4;513(7516):65-70. doi: 10.1038/nature13485. Epub 2014 Jul 27.

27.

Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo.

Polykratis A, Hermance N, Zelic M, Roderick J, Kim C, Van TM, Lee TH, Chan FKM, Pasparakis M, Kelliher MA.

J Immunol. 2014 Aug 15;193(4):1539-1543. doi: 10.4049/jimmunol.1400590. Epub 2014 Jul 11.

28.

Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.

Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A.

Cancer Discov. 2014 Sep;4(9):1074-87. doi: 10.1158/2159-8290.CD-14-0353. Epub 2014 Jul 3.

29.

RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3.

Dillon CP, Weinlich R, Rodriguez DA, Cripps JG, Quarato G, Gurung P, Verbist KC, Brewer TL, Llambi F, Gong YN, Janke LJ, Kelliher MA, Kanneganti TD, Green DR.

Cell. 2014 May 22;157(5):1189-202. doi: 10.1016/j.cell.2014.04.018. Epub 2014 May 8.

30.

Caspase-8 and RIP kinases regulate bacteria-induced innate immune responses and cell death.

Weng D, Marty-Roix R, Ganesan S, Proulx MK, Vladimer GI, Kaiser WJ, Mocarski ES, Pouliot K, Chan FK, Kelliher MA, Harris PA, Bertin J, Gough PJ, Shayakhmetov DM, Goguen JD, Fitzgerald KA, Silverman N, Lien E.

Proc Natl Acad Sci U S A. 2014 May 20;111(20):7391-6. doi: 10.1073/pnas.1403477111. Epub 2014 May 5.

31.

Leukemia propagating cells Akt up.

Gutierrez A, Roderick JE, Kelliher MA.

Cancer Cell. 2014 Mar 17;25(3):263-5. doi: 10.1016/j.ccr.2014.02.022.

32.

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.

Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, Gillespie SM, Fernandez D, Ku M, Wang H, Piccioni F, Silver SJ, Jain M, Pearson D, Kluk MJ, Ott CJ, Shultz LD, Brehm MA, Greiner DL, Gutierrez A, Stegmaier K, Kung AL, Root DE, Bradner JE, Aster JC, Kelliher MA, Bernstein BE.

Nat Genet. 2014 Apr;46(4):364-70. doi: 10.1038/ng.2913. Epub 2014 Mar 2.

33.

Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.

Reynolds C, Roderick JE, LaBelle JL, Bird G, Mathieu R, Bodaar K, Colon D, Pyati U, Stevenson KE, Qi J, Harris M, Silverman LB, Sallan SE, Bradner JE, Neuberg DS, Look AT, Walensky LD, Kelliher MA, Gutierrez A.

Leukemia. 2014 Sep;28(9):1819-27. doi: 10.1038/leu.2014.78. Epub 2014 Feb 20.

34.

c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.

Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, Harris MH, Silverman LB, Sallan SE, Gutierrez A, Look AT, Qi J, Bradner JE, Kelliher MA.

Blood. 2014 Feb 13;123(7):1040-50. doi: 10.1182/blood-2013-08-522698. Epub 2014 Jan 6.

35.

Activation of NOD receptors by Neisseria gonorrhoeae modulates the innate immune response.

Mavrogiorgos N, Mekasha S, Yang Y, Kelliher MA, Ingalls RR.

Innate Immun. 2014 May;20(4):377-89. doi: 10.1177/1753425913493453. Epub 2013 Jul 24.

36.

The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.

Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA, Jamieson CH, von Boehmer H, Young RA, Look AT.

J Exp Med. 2013 Jul 29;210(8):1545-57. doi: 10.1084/jem.20122516. Epub 2013 Jul 15.

37.

RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3.

Lukens JR, Vogel P, Johnson GR, Kelliher MA, Iwakura Y, Lamkanfi M, Kanneganti TD.

Nature. 2013 Jun 13;498(7453):224-7. doi: 10.1038/nature12174. Epub 2013 May 26.

38.

TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT.

Cancer Discov. 2013 May;3(5):564-77. doi: 10.1158/2159-8290.CD-12-0504. Epub 2013 Mar 7.

39.

Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

Sawai CM, Freund J, Oh P, Ndiaye-Lobry D, Bretz JC, Strikoudis A, Genesca L, Trimarchi T, Kelliher MA, Clark M, Soulier J, Chen-Kiang S, Aifantis I.

Cancer Cell. 2012 Oct 16;22(4):452-65. doi: 10.1016/j.ccr.2012.09.016.

40.

NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro.

Simmons MJ, Serra R, Hermance N, Kelliher MA.

Breast Cancer Res. 2012 Sep 19;14(5):R126. doi: 10.1186/bcr3321.

41.

Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia.

Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson CH, Staudt LM, Young RA, Look AT.

Cancer Cell. 2012 Aug 14;22(2):209-21. doi: 10.1016/j.ccr.2012.06.007.

42.

Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.

Tatarek J, Cullion K, Ashworth T, Gerstein R, Aster JC, Kelliher MA.

Blood. 2011 Aug 11;118(6):1579-90. doi: 10.1182/blood-2010-08-300343. Epub 2011 Jun 13.

43.

A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage.

Yang Y, Xia F, Hermance N, Mabb A, Simonson S, Morrissey S, Gandhi P, Munson M, Miyamoto S, Kelliher MA.

Mol Cell Biol. 2011 Jul;31(14):2774-86. doi: 10.1128/MCB.01139-10. Epub 2011 May 23.

44.

A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.

Draheim KM, Hermance N, Yang Y, Arous E, Calvo J, Kelliher MA.

Oncogene. 2011 Mar 10;30(10):1252-60. doi: 10.1038/onc.2010.495. Epub 2010 Nov 8.

45.

Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide.

Coulombe F, Divangahi M, Veyrier F, de Léséleuc L, Gleason JL, Yang Y, Kelliher MA, Pandey AK, Sassetti CM, Reed MB, Behr MA.

J Exp Med. 2009 Aug 3;206(8):1709-16. doi: 10.1084/jem.20081779. Epub 2009 Jul 6.

46.

NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis.

Pandey AK, Yang Y, Jiang Z, Fortune SM, Coulombe F, Behr MA, Fitzgerald KA, Sassetti CM, Kelliher MA.

PLoS Pathog. 2009 Jul;5(7):e1000500. doi: 10.1371/journal.ppat.1000500. Epub 2009 Jul 3.

47.

Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.

Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C, Nikov G, Krishnamoorthy V, Majumder PK, Kelliher MA.

Blood. 2009 Jun 11;113(24):6172-81. doi: 10.1182/blood-2008-02-136762. Epub 2009 Feb 26.

48.

RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR.

Ramnarain DB, Paulmurugan R, Park S, Mickey BE, Asaithamby A, Saha D, Kelliher MA, Mukhopadhyay P, Banani F, Madden CJ, Wright PS, Chakravarty S, Habib AA.

Cell Death Differ. 2008 Feb;15(2):344-53. Epub 2007 Nov 16.

49.

NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2.

Yang Y, Yin C, Pandey A, Abbott D, Sassetti C, Kelliher MA.

J Biol Chem. 2007 Dec 14;282(50):36223-9. Epub 2007 Oct 18.

50.

Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains.

Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC.

Mol Cell Biol. 2007 Sep;27(17):6012-25. Epub 2007 Jun 11.

Supplemental Content

Loading ...
Support Center